Tag: Etravirine

According to the U.S. Food and Drug Administration (FDA), etravirine was approved for the treatment of HIV-1 infection in treatment-experienced adults in 2007. The other name for etravirine, the generic name for this HIV medication, is its brand name, Intelence®.

According to Pharmacy Practice News, the first generic version of etravirine was approved by the FDA in July 2021. The generic for etravirine has the same active ingredient as the brand-name drug Intelence, and is also known by its chemical name, etravirine.

First approved by the FDA in 2008 for treatment-experienced HIV patients, etravirine, known by the brand name Intelence, is a second-generation NNRTI, and the answer to *is etravirine still available?* is yes, it is. Generic versions have also been approved and are on the market, expanding access to this important antiretroviral therapy.

Etravirine, a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved by the FDA in 2008 for treatment-experienced adults with HIV-1. Its key role is in combination therapy for patients who have developed resistance to earlier antiretroviral drugs, making it an essential tool for managing difficult-to-treat infections.